Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peptide receptor radionuclide therapy.

Eric P Krenning1, Dik J Kwekkeboom, Roelf Valkema

  • 1Department of Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. e.p.krenning@erasmusmc.nl

Annals of the New York Academy of Sciences
|May 22, 2004
PubMed
Summary

Radiolabeled peptide analogues target tumors expressing specific receptors, forming the basis for advanced imaging and peptide receptor radionuclide therapy (PRRT). Combining radionuclides and targeting multiple receptors shows promise for improved cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [<sup>177</sup>Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial.

Cancer medicine·2025
Same author

Reshaping [<sup>99m</sup>Tc]Tc-DT11 to DT14D Tagged with Trivalent Radiometals for NTS<sub>1</sub>R-Positive Cancer Theranostics.

Pharmaceutics·2025
Same author

Diagnosis of Prostate Cancer with a Neurotensin-Bombesin Radioligand Combination-First Preclinical Results.

Pharmaceutics·2024
Same author

Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [<sup>111</sup>In]In-Radioligands: Synthesis and Preclinical Profile.

International journal of molecular sciences·2024
Same author

Side-Chain Modified [<sup>99m</sup>Tc]Tc-DT1 Mimics: A Comparative Study in NTS<sub>1</sub>R-Positive Models.

International journal of molecular sciences·2023

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Molecular Imaging

Background:

  • Cell surface receptors, like somatostatin receptors, are overexpressed in many tumors.
  • Radiolabeled peptide analogues targeting these receptors enable tumor visualization and therapy.

Purpose of the Study:

  • To review the development and application of peptide receptor radionuclide therapy (PRRT) for receptor-positive tumors.
  • To explore novel strategies for enhancing PRRT efficacy, including combination therapies and multireceptor targeting.

Main Methods:

  • Development of radiolabeled peptide analogues (e.g., somatostatin, minigastrin, bombesin, NPY(Y(1))) for imaging and therapy.
  • Application of peptide receptor radionuclide therapy (PRRT) in preclinical and clinical studies.
  • Investigating methods to improve therapeutic window, such as amino acid infusions.

Related Experiment Videos

  • Exploring combination of different radionuclides and peptide targeting strategies.

    • Main Results:

    • Radiolabeled somatostatin analogues are effective in treating receptor-positive tumors.
    • Radiolabeled minigastrin analogues are used for CCK-B receptor-positive tumors like medullary thyroid carcinoma.
    • Combination of radionuclides (e.g., (177)Lu, (90)Y) and multireceptor targeting show potential for improved outcomes.

    Conclusions:

    • Peptide receptor radionuclide therapy (PRRT) is an effective treatment modality for various receptor-positive cancers.
    • Ongoing research into novel peptide analogues and combination therapies promises to further enhance cancer treatment efficacy and patient outcomes.